Durable Response to Glofitamab in HIV‐Positive Refractory Burkitt Lymphoma: Case Report and Discussion

TL;DR

A 60-year-old HIV-positive patient with refractory Burkitt lymphoma achieved complete remission after treatment with glofitamab, suggesting it could be a promising treatment option.

Contribution

This case report demonstrates the successful use of glofitamab in an HIV-positive patient with refractory Burkitt lymphoma.

Findings

Twelve cycles of glofitamab led to complete metabolic remission in the patient.

The remission was sustained for nine months post-treatment.

Glofitamab may serve as a stand-alone treatment option for relapsed Burkitt lymphoma.

Abstract

Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed.

We describe a 60‐year‐old HIV‐positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off‐label with glofitamab successfully.

Twelve cycles of glofitamab were well tolerated and led to complete metabolic remission confirmed by imaging and biopsy, sustained for nine months post‐treatment.

Glofitamab may represent a promising stand‐alone option in relapsed BL, when conventional cytotoxic therapies are exhausted.

Clinical Trial Registration: The authors have confirmed that clinical trial registration is not needed for this submission.

Figures